2016 Fear vs Hope: Gene Editing— Terrible turning point?
By Pete Shanks,
Deccan Chronicle
| 01. 01. 2017
The next year may represent our best chance to prevent the rise of a modern, uncontrolled and dangerously ill-considered techno-eugenics.
If new “gene editing” tools can be used to treat people who are sick, that would be a hugely welcome development. But applying them to human reproduction could all too easily open the door to a world of genetic haves and have-nots. Will it be possible for the distinction between responsible and irresponsible applications of human genetic technologies to hold, in policy and in practice? There is hope, but the signals from 2016 are very worrying.
One year ago, the U.S. National Academies Summit on Human Gene Editing ended with a consensus statement that proceeding with inheritable (germline) gene editing would be “irresponsible” until both the science was proven and there was “broad societal consensus about the appropriateness of the proposed application.”
It didn’t take long for that to seem wildly optimistic. Even before that announcement, and in complete secrecy, a rogue American scientist had defied authorities by using Mexican facilities to create a baby for a Jordanian couple using...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...